Novartis is reimagining medicine to improve and extend people's lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. Novartis products reach nearly 1 billion people globally and we are finding innovative ways to expand access to our latest treatments. About 125,000 people of more than 140 nationalities work at Novartis around the world.
Business & Industry
- Pfizer and Clear Creek Bio to collaborate on a research program targeting SARS-CoV-2 papain-like protease
- Bayer supports rebuilding of Ukrainian healthcare system by donating 1.3 million euros
- Eisai and Biogen announced the results from large global Phase 3 confirmatory Clarity AD clinical study of lecanemab
- AstraZeneca to acquire Neogene Therapeutics, accelerating ambition in Oncology cell therapy
- Pfizer and BioNTech report new data on Omicron BA.4/BA.5-adapted bivalent booster
Research & Development
- New receptor "decoy" drug neutralizes COVID-19 virus and its variants
- New clue discovered for how and why cancer cells spread
- Nanotech strategy shows promise for treating autoimmune disease
- The first potent COQ8 inhibitor targets ubiquinone biosynthesis
- AI tailors artificial DNA for future drug development
- Remdesivir reduces COVID-19 mortality in a real-world setting
- Pocket feature shared by deadly coronaviruses could lead to pan-coronavirus antiviral treatment
Conferences & Events
- 14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
- CPHI Excellence in Pharma Award Winners 2022
- CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth
- CPHI Frankfurt 2022: Global pharma confidence hits record high in the annual CPHI Pharma Index
- SAE Media Group proudly presents the 2nd Annual Aseptic Processing Conference
- Pharma join together to achieve new standards in digital and patient innovation for clinical transformation
- SMi's 22nd Annual Pain Therapeutics Conference
Regulatory Affairs
- FDA approves first gene therapy to treat adults with Hemophilia B
- FDA approves first treatment for Acid Sphingomyelinase Deficiency, a rare genetic disease
- FDA approves first systemic treatment for alopecia areata
- FDA urges drug manufacturers to develop risk management plans to promote a dtronger, resilient drug supply chain
- FDA limits use of Janssen COVID-19 vaccine to certain individuals